122 results on '"R, Strohal"'
Search Results
2. Author Correction: Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trial
- Author
-
R. Strohal, S. Dietrich, M. Mittlböck, and G. Hämmerle
- Subjects
Medicine ,Science - Published
- 2022
- Full Text
- View/download PDF
3. Erratum: Gesundheitsökonomische Aspekte der Kaltplasmatherapie: exemplarische Betrachtung der Versorgung chronischer Wunden mithilfe des Plasmajet kINPen MED
- Author
-
J Witte, D. Gensorowsky, A. Zeitler, W. Greiner, and R. Strohal
- Subjects
Health Policy - Published
- 2023
4. Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trial
- Author
-
R. Strohal, S. Dietrich, M. Mittlböck, and G. Hämmerle
- Subjects
Wound Healing ,Multidisciplinary ,integumentary system ,Humans ,Prospective Studies ,Bandages - Abstract
The use of phase-adapted wound dressings represents best practice (BP) in chronic wound treatment. However, efficacy is often limited and associated care requirements are high. Cold atmospheric plasmajet (CAP-jet) is a promising new therapeutic tool for these wounds. In the present multicenter, randomized, open-label, prospective, clinical trial, non-inferiority of the CAP-jet versus BP was assessed in 78 patients with infected or non-infected chronic wounds of different etiology. Primary outcome measure was the sum of granulation tissue, furthermore wound area reduction, healing rate, time to complete healing, changes in wound pH value, infection score, exudate level and local tolerability were assessed. In CAP-jet treated wounds compared to control, the sum of granulation tissue was significantly higher (p
- Published
- 2021
5. Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey
- Author
-
G Richtig, M Richtig, W Hoetzenecker, W Saxinger, B Lange-Asschenfeldt, A Steiner, R Strohal, C Posch, J Bauer, R Müllegger, T Deinlein, N Sepp, B Volc-Platzer, V Nguyen, M Schmuth, C Hoeller, E Muehlbacher, G Pregartner, and E Richtig
- Subjects
Adult ,Male ,knowledge ,Health Knowledge, Attitudes, Practice ,medicine.medical_specialty ,Attitude of Health Personnel ,Clinical Decision-Making ,Scientific Misconduct ,Dermatology ,Scientific literature ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,survey ,Prospective Studies ,030212 general & internal medicine ,influence ,physician ,business.industry ,030206 dentistry ,General Medicine ,Middle Aged ,Open Access Publishing ,RL1-803 ,Austria ,Female ,Periodicals as Topic ,business ,predatoryjournal ,dermatologist ,Dermatologists - Abstract
The aim of this study was to assess the knowledge and influence of predatory journals in the field of dermatology in Austria. A total of 286 physicians (50.5% men) completed a questionnaire. The vast majority of subjects read scientific articles (n = 281, 98.3%) and took them into consideration in their clinical decision-making (n = 271, 98.5% of participants that regularly read scientific literature). Open access was known by 161 (56.3%), predatory journals by 84 (29.4%), and the Beall's list by 19 physicians (6.7%). A total of 117 participants (40.9%) had been challenged by patients with results from the scientific literature, including 9 predatory papers. Participants who knew of predatory journals had a higher level of education as well as scientific experience, and were more familiar with the open-access system (p < 0.001). These results indicate that the majority of dermatologists are not familiar with predatory journals. This is particularly the case for physicians in training and in the early stages of their career.
- Published
- 2018
6. [Chronic, refractory ulcer on the ring finger : Manifestation of distal epithelioid sarcoma]
- Author
-
N S, Häring, R, Strohal, S, Dertinger, and F, Offner
- Subjects
Male ,Sentinel Lymph Node Biopsy ,Skin Ulcer ,Humans ,Sarcoma ,Soft Tissue Neoplasms ,Neoplasm Recurrence, Local - Abstract
The epithelioid sarcoma classic, "distal" type was first published in 1970. It is a very rare, malignant, aggressive subcutaneous soft tissue sarcoma that shows characteristic positivity for both epithelial and mesenchymal immunohistochemical markers. It grows very slowly and mostly presents in young men. Clinically the tumor is characterized as a coarse cutaneous or subcutaneous nodular induration that often ulcerates in the course of the disease. An association with trauma is often described and can lengthen time to diagnosis. Most frequently it is found on the flexural side of fingers, the back of the hands, soles of the feet, and extensor sides of arms and legs. Specific for this type of sarcoma is the progression along nerves, tendons, and fasciae. Treatment of choice should be wide excision of the tumor, sentinel node biopsy, and possibly even localized postoperative radiation therapy. Unfortunately the epithelioid sarcoma is very likely to recur and is then associated with metastases in the lung and lymph nodes.
- Published
- 2017
7. The Combination Of Fractionated Erbium:YAG Laser Skin Microporation And Topical Imiquimod Is A New, Safe And Efficient Strategy For The Treatment Of Actinic Keratosis And Basal Cell Carcinoma: Report Of Two Pilot Studies
- Author
-
S. Dertinger, C. Boehler, N. Haering, K. Barlas, and R. Strohal
- Subjects
medicine.medical_specialty ,Skin erythema ,business.industry ,Actinic keratosis ,Imiquimod ,Erbium-YAG laser ,medicine.disease ,Dermatology ,Dose finding ,Tolerability ,medicine ,Basal cell carcinoma ,Topical imiquimod ,business ,medicine.drug - Abstract
Background Imiquimod has shown to be efficacious in basal cell carcinoma and actinic keratosis, but with therapeutic burden such as strong skin reactions and long treatment periods. Objectives To compare the safety and efficacy of different application frequencies of the new laser skin microporation device combined with topical 5% imiquimod and the standard use of imiquimod alone for the treatment of actinic keratosis and basal cell carcinomas. Methods In two prospective, randomised, dose finding, pilot studies for basal cell carcinoma and actinic keratosis, we used either imiquimod alone according to the approved dosage (control arm 1) or on microporated skin for 1x/2x/3x/week (arm 1-4), respectively. Strength of imiquimod-induced skin reactions at day 20 (study end) represented the primary endpoint. Secondary study parameters comprised the development and strength of skin erythema including crusting and erosions during the whole study, clearence at day 20 and tolerability as well as safety parameters. Results In both studies (patients/lesions treated and analysed: basal cell carcinoma 16/20 and 13/15; actinic keratosis 18/21 and 13/15) the combined laser and imiquimod therapy led to stronger skin erythema, crusting and erosion levels in the early study phase. Well tolerated without new safety signals, total clearence rates (arms 2-4/control arm 1) were 78%/75% (basal cell carcinoma) and 77%/50% (actinic keratosis), respectively. Conclusions We suggest to call this new treatment approach laser dynamic therapy. Based on our data, the most appropriate laser and imiquimod application frequency might be 2x/week (2-3 shots each at 3 pulses) with a suggested time to heal of 3 weeks. Further studies with larger patient cohorts are needed to substantiate our data. J O U R N A L O F D E R M A T O L O G I C A L R E S E A R C H A N D T H E R A P Y ISSN NO: 2471-2175 RESEARCH DOI : 10.14302/issn.2471-2175.jdrt-14-552 Corresponding Author: Robert Strohal, MD; Professor of Dermatology, Head of Dep. Dept. of Dermatology and Venereology; Federal Academic Teaching Hospital Feldkirch Carinagasse 45-47, 6800 Feldkirch; Austria Telephone: +43/5522/303.1200,-9121; Mobile: +43/664/1142140; Fax: +43/5522/303-7547 Robert.strohal@lkhf.at Running title: Skin microporation and imiquimod in actinic keratosis and basal cell carcinoma
- Published
- 2015
8. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone
- Author
-
P. Lohse, R. Strohal, J. Staub, Sergij Goerdt, Martin Leverkus, N. Pfannschmidt, and Markus Braun-Falco
- Subjects
medicine.medical_specialty ,Dermatology ,Dapsone ,Etanercept ,Young Adult ,Anti-Infective Agents ,Acne Vulgaris ,medicine ,Adalimumab ,Humans ,Hidradenitis suppurativa ,skin and connective tissue diseases ,Anakinra ,business.industry ,Syndrome ,PAPA syndrome ,medicine.disease ,Infliximab ,Pyoderma Gangrenosum ,Hidradenitis Suppurativa ,Infectious Diseases ,Cyclosporine ,Drug Therapy, Combination ,Female ,Dermatologic Agents ,business ,Immunosuppressive Agents ,Pyoderma gangrenosum ,medicine.drug - Abstract
Background The group of autoinflammatory syndromes associated with Pyoderma gangrenosum, Acne, and Suppurative Hidradenitis are poorly defined and difficult to control with currently available treatment modalities. Objectives We describe a patient with PASH syndrome and report about the successful multimodal treatment with infliximab, cyclosporine, and dapsone. Methods A review of the available literature to date about this group of autoinflammatory diseases was performed. We performed genetic analysis for PSTPIP1 mutations associated with PAPA syndrome. Results A 22-year-old woman presented to our department with pyoderma gangrenosum, concomitant acne, and suppurative hidradenitis. She had previously been treated unsuccessfully with etanercept, adalimumab, fumaric acid and the IL-1 receptor antagonist (IL-1RA) anakinra without prolonged remission. Treatment with intravenous infliximab in combination with cyclosporine and dapsone lead to sudden and prolonged improvement of the clinical symptoms that we classified as PASH syndrome. We review the literature about this group of diseases and report the third case of PASH syndrome to date. Conclusion PASH syndrome and associated diseases should be considered whenever hidradenitis suppurativa is found in association with pyoderma gangrenosum. We provide a systematic overview about PASH syndrome and suggest a novel multimodal therapeutic regimen beyond isolated inhibition of TNF or IL-1.
- Published
- 2014
9. Allergologische Therapie und Lebensqualität des Patienten bei allergischer Rhinitis
- Author
-
R. Strohal
- Abstract
Bei der allergischen Rhinitis handelt es sich um ein weltweit unterschatztes Gesundheitsproblem. Untersuchungen zeigen, dass neben den belastenden Symptomen selbst auch das soziale Leben, der Schlaf sowie Schul- und Arbeitsleistungen durch die ganzjahrigen oder saisonalen Beschwerden mitunter erheblich beeintrachtigt werden. Auch die anfallenden Kosten durch Krankenstande, schulische Fehlzeiten sowie Produktivitatsausfalle sind erheblich. Zudem kann eine zu spat oder unbehandelte allergische Rhinitis schwere Folgeerkrankungen nach sich ziehen (z. B. allergisches Asthma). Die spezifische Immuntherapie ist die einzige kausale Therapie einer allergischen Rhinitis und kann bei allergischen Patienten nicht nur die Symptome und den Verbrauch symptomatischer Medikamente reduzieren, sondern auch die Lebensqualitat der Betroffenen deutlich verbessern. Um die subjektiven Einschatzungen von einzelnen Patienten zur Lebensqualitat objektivierbar und damit auch statistisch messbar machen, dienen in erster Linie standardisierte und validierte Fragebogen. Fur die schnelllosliche Grasertablette GRAZAX® wurde in mehreren grosen Studien belegt, dass die Therapie neben einer guten Wirksamkeit und Sicherheit auch eine signifikante Verbesserung der Lebensqualitat fur Graserpollen-allergische Patienten aufweist.
- Published
- 2014
10. [Wound management with enzyme alginogels : Expert consensus]
- Author
-
R, Strohal, B, Assenheimer, M, Augustin, G, Hämmerle, S, Läuchli, B, Pundt, G, Stern, M, Storck, and C, Ulrich
- Subjects
Wound Healing ,Evidence-Based Medicine ,Alginates ,Dermatology ,Bandages ,Combined Modality Therapy ,Lacerations ,Anti-Bacterial Agents ,Treatment Outcome ,Debridement ,Germany ,Practice Guidelines as Topic ,Humans ,Oxidoreductases ,Expert Testimony - Abstract
The challenges of modern wound management, such as the treatment of chronic wounds and their phase-specific handling, are demanding and require optimally adapted therapeutic measures. The principles of moist wound care as well as an adequate debridement have priority here. To support these necessary measures, different options are available, e.g., a new product group operating across several wound phases.A new treatment principle in modern wound management based on an expert consensus is presented.On the basis of clinical experience reports and published evidence, the current and new principles of wound treatment were discussed in a panel of experts and formulated as a consensus statement.Enzyme alginogels represent a combination of agents that allow phase-specific wound care. They exhibit autolytic, absorbent, and antimicrobial properties and simultaneously cover three components of wound management based on the TIME framework. Thus, according to the experts, they differ from other wound healing products and can be classified in a distinct product group. Clinical studies, as well as clinical experiences, provide evidence for the efficacy of enzyme alginogels.According to the experts, the potential of enzyme alginogels used considering the principles of moist wound care, comprises the three-fold effect (continuous and significantly simplified debridement, maintaining a moist wound environment and antimicrobial effect without cytotoxicity), the ease of use, and the flexible application. In addition, the flexibility of the product class regarding frequency of application, duration of treatment and combinability with secondary dressings, are of economic benefit in the health care sector.
- Published
- 2016
11. An updated overview and clarification of the principle role of debridement
- Author
-
R, Strohal, J, Dissemond, J, Jordan O'Brien, A, Piaggesi, R, Rimdeika, T, Young, and J, Apelqvist
- Subjects
Wound Healing ,Debridement ,Disease Management ,Humans ,Wounds and Injuries - Abstract
Routine care of non-healing acute and chronic wounds often comprises either cleaning or debridement. Consequently, debridement is a basic necessity to induce the functional process of tissue repair, which makes it a central medical intervention in the management of acute and chronic, non-healing wounds.
- Published
- 2013
12. Early detection of renal damage caused by fumaric acid ester therapy by determination of urinary β2-microglobulin
- Author
-
M. Mündle, K. Lhotta, H. Sprenger Mähr, R. Strohal, and N. Häring
- Subjects
Kidney ,medicine.medical_specialty ,Fumaric acid ,Creatinine ,business.industry ,Urinary system ,Acute kidney injury ,Urology ,Fanconi syndrome ,Renal function ,Dermatology ,medicine.disease ,Surgery ,Excretion ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,medicine ,business - Abstract
Summary Background Fumaric acid esters are considered efficacious and safe drugs for the treatment of psoriasis. Renal damage, caused either by acute renal injury or Fanconi syndrome, is a recognized side-effect of this therapy. Objectives To investigate whether the measurement of urinary excretion of β2-microglobulin, a marker of renal proximal tubular dysfunction, allows early detection of kidney damage before an increase in serum creatinine or significant proteinuria occurs. Methods Urinary β2-microglobulin excretion was measured regularly in 23 patients undergoing fumaric acid ester therapy. Results Urinary β2-microglobulin remained normal in all 10 male patients. Three (23%) out of 13 female patients experienced an increase in urinary β2-microglobulin excretion. In two of these patients a sharp increase was observed in association with high doses. One further patient had moderately elevated levels on rather low doses of fumaric acid esters. After discontinuing treatment, urinary β2-microglobulin levels returned to normal within a few weeks. Conclusion Determination of urinary β2-microglobulin possibly allows early detection of renal damage by fumaric acid esters. Female patients seem to be prone to this side-effect, especially when taking high doses.
- Published
- 2011
13. Fetal skin: a site of dendritic epidermal T cell development
- Author
-
A Elbe, O Kilgus, R Strohal, E Payer, S Schreiber, and G Stingl
- Subjects
Immunology ,Immunology and Allergy - Abstract
Thy-1 Ag and CD3-associated TCR-gamma (V gamma 3)/delta (V delta 1) are coexpressed on virtually all dendritic epidermal T cells (DETC) in the adult mouse. In contrast, day 16 fetal mouse skin contains small numbers of CD45+/Thy-1+/CD3- but no CD3+ cells. To see whether the CD45+/Thy-1+/CD3- fetal skin cells can qualify as DETC precursors, we transplanted day 16 fetal skin of C57BL/6 (Thy-1.2) mice onto adult B6Pl-Thy-1a (Thy-1.1) animals. At certain time points after transplantation, grafts were analyzed for the presence of Thy-1 and CD3/TCR Ag. Examination of the grafts, 4 days after transplantation, revealed the presence of few donor-type Thy-1.2+/CD3- and some Thy-1.2+/CD3+ epidermal cells of either round or dendritic configuration. At 10 weeks after transplantation, essentially all CD45+/Thy-1.2+ epidermal cells were anti-TCR V gamma 3 and anti-CD3-reactive, displayed a uniformly dendritic configuration, and, thus, represent DETC. Our assumption that CD45+/Thy-1+/CD3- cells are the only lymphocytes within day 16 fetal skin gained additional support by the observations: 1) that unfractionated as well as anti-CD45 gated single cell suspensions prepared from day 16 fetal skin were consistently devoid of anti-CD3 epsilon and anti-TCR V gamma 3-reactive cells; and 2) that stimulation of these cell suspensions with either Con A plus IL-2 or IL-2 alone regularly resulted in the outgrowth of CD45+/Thy-1+/CD3-/TCR V gamma 3- cells, but never in the appearance of CD45+/Thy-1+/CD3+/TCR V gamma 3+ cells. Our additional finding that Con A plus IL-2- or IL-2-stimulated day 16 fetal skin cells and cell lines derived therefrom contain transcripts of some (CD3 gamma, TCR C beta, TCR C gamma 1, TCR C gamma 4) but not of other (CD3 delta, CD3 epsilon, TCR C alpha, TCR C delta) genes encoding the CD3/TCR complex suggests that Thy-1+/CD3- fetal murine skin cells are of T cell lineage. We therefore propose that the fetal skin microenvironment can provide the stimuli promoting growth and maturation of CD3/TCR V gamma 3/V delta 1-expressing DETC from their CD3- precursors.
- Published
- 1992
14. Demonstration of a CD3+ lymphocyte subset in the epidermis of athymic nude mice. Evidence for T cell receptor diversity
- Author
-
E Payer, R Strohal, R Kutil, A Elbe, and G Stingl
- Subjects
Immunology ,Immunology and Allergy - Abstract
The existence of CD3/TCR-bearing lymphocytes in athymic and thymectomized chimeric mice implies that T cell maturation can occur in the absence of a thymus. Considering the possibility that the epidermis may be one of the organs providing T cell educating stimuli, we attempted to characterize the Thy-1+ epidermal lymphocyte population of athymic mice. Immunohistologic studies of epidermal sheets revealed (1) that Thy-1+ epidermal cells of C57BL/6 nu/nu mice are CD5-, CD4-, and predominantly CD8-, and (2) that a minor subset of these cells displays anti-CD3 epsilon reactivity. Although these CD3+ epidermal cells could hardly be detected at 6 wk of age, they comprised approximately 2% of all Thy-1+ epidermal cells in 12-mo-old athymic mice. Most of these CD3+ cells expressed TCR-gamma/delta, but TCR-alpha/beta+ cells were also present. TCR-gamma/delta+ epidermal T cells of athymic mice preferentially expressed TCR V gamma 2, V gamma 4, and V gamma 5 specificities rather than TCR V gamma 3 as found on DETC of euthymic mice. Using mitogenic stimuli, we have succeeded in establishing cell lines and clones from BALB/c nu/nu and C57BL/6 nu/nu epidermis. Their marker profile corresponds to that seen on resident CD3+ epidermal cells, as well as on a very small subset of CD3+ splenic and lymph node lymphocytes of athymic mice. The ontogenetic relationship, if any, between the epidermal and lymphoid CD3+, CD5-, CD4-, CD8- cells, has yet to be clarified. Cell lines/clones representative of resident CD3+ epidermal cells of nu/nu mice should provide a useful tool in the elucidation of homing patterns and functional properties of extrathymically matured T cells.
- Published
- 1992
15. Localized vs generalized pyogenic granuloma. A clinicopathologic study
- Author
-
R. Strohal
- Subjects
Dermatology ,General Medicine - Published
- 1991
16. Contents, Vol. 182, 1991
- Author
-
V. Ramesh, G. Orecchia, P.H. McKee, C. Torresani, M. Cespa, E. Akiyoshi, O.M.V. Schofield, A. Hidano, J. Spona, A. Tamir, R. Yamaguchi, Antonella Tosti, S. Okamoto, Gérald Pierard, H. Toyoda, E. Tanabe, R.S. Misra, U. Saxena, G. De Panfilis, T. Terano, A.M. Kligman, A. Lindmaier, Cosimo Misciali, Sarah Brenner, P. A. Fanti, William Hanke, R. Wolf, T. Kojima, B.J. Mayou, P. Borrello, R. Grimalt, T. Lazzari, R. Strohal, Y. Tamura, A. Nume, C. Piérard-Franchimont, Ruggero Caputo, L. Perfetti, Annalisa Patrizi, W. Aberer, F. Bardazzi, D.P. Bruynzeel, Robin A.J. Eady, Makoto Kawashima, S. Yoshida, G.C. Manara, A. Rebora, R.C. Beljaards, E. Berti, L. Fina, T. Nogita, C. Ferrari, A. Parodi, J.B. Schmidt, and John A. McGrath
- Subjects
Dermatology - Published
- 1991
17. Development and Implementation of Process-Oriented Skin Safety Standards for the Mineral Oil Industry: A Pilot Study
- Author
-
R. Taibl, R. Strohal, M. Mittlböck, G. Payer-Neundlinger, N. Speiser-Rankine, and W. Unterberger
- Subjects
Engineering ,integumentary system ,business.industry ,Process oriented ,medicine ,Safety standards ,Mineral oil ,business ,Manufacturing engineering ,medicine.drug - Abstract
Summary Occupational skin diseases are among the most frequent causes for disablement. Although workers in the oil, gas and petrol industry are especially exposed to a variety of skin toxic/irritating substances, no data exists on the extent of the problem and how to define/introduce adequate skin protection measures. As a pilot, a 3 phase skin disease prevention and safety program was created for the Austrian OMV location at Gaenserndorf. Phase 1 (examination phase) showed that workers who substantially lacked information on dermal risk factors and behavior presented with irritant contact dermatitis of the hands at a rate of 55.4%. In addition, the company offered 27 different skin cleaning, protection and care products which were not clearly in line with workplace specific patterns of chemical skin burden. To specifically target these problems, phase 2 (realization phase) introduced new workplace adapted skin products with defined location specific sets of dispensers labeled for the role of its products, introduced skin safety plans at workplaces and a series of teaching courses based an a standardized newly developed education slide kit. By re-assessing (phase 3, evaluation phase) the most objective phase 1 parameters for the quality of skin protection measures, we found a decrease of the rate of irritant hand dermatitis from 55.4% to 19.7% and the rate of uninformed workers got down from about 60% to 20%. Taken together, the process oriented, skin safety standards herein presented have shown to specifically identify, analyze, target and unravel the relevant company related features of occupational skin diseases. The basic structure and design of this programme might be suggestive for its health supportive role in the oil, gas and petrol industry as a whole.
- Published
- 2006
18. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem
- Author
-
M. Takacs, M. Schelling, F. Offner, U. Gruber, W. Jurecka, and R. Strohal
- Subjects
Microbiology (medical) ,Staphylococcus aureus ,Meticillin ,Micrococcaceae ,Silver ,medicine.drug_class ,Antibiotics ,medicine.disease_cause ,Microbiology ,medicine ,Infection control ,Humans ,Antibacterial agent ,Cross Infection ,Infection Control ,integumentary system ,biology ,business.industry ,General Medicine ,Staphylococcal Infections ,Antimicrobial ,biology.organism_classification ,Bandages ,Nanocrystalline material ,Infectious Diseases ,Wound Infection ,Methicillin Resistance ,business ,medicine.drug - Abstract
The emergence of multi-drug-resistant strains of bacteria represents a particular challenge in the field of wound management. The aim of the current study was to investigate whether nanocrystalline silver dressings possess the physical properties to act as a barrier to the transmission of methicillin-resistant Staphylococcus aureus (MRSA) in the laboratory setting and in a clinical setting. Initially, MRSA suspension and colony culture experiments were performed showing that nanocrystalline silver dressings act as potent and sustained antimicrobial agents, efficiently inhibiting MRSA penetration. Subsequently, a double-centre clinical trial was initiated using nanocrystalline silver dressings as a cover for 10 MRSA colonized wounds in a total of seven patients. By delineating the MRSA load on the upper side of the dressing and the wound bed each time the dressing was changed (i.e. after 1, 24, 48 and 72 h), nanocrystalline silver dressings were found to provide a complete, or almost complete, barrier to the penetration/spread of MRSA in 95% of readings. In addition, 67% of all wound observations showed a decrease in the MRSA load with an eradication rate of 11%. We believe that nanocrystalline silver dressings may become an important part of local MRSA management, with cost benefits to both patients and the healthcare system.
- Published
- 2004
19. Malignes Melanom
- Author
-
A. Schneeberger, R. Strohal, and G. Stingl
- Published
- 2004
20. [The importance of HIV-1 in dentistry, oral medicine and orthodontics. A virological, epidemiological and clinical update]
- Author
-
G, Kofler, I, Moschèn, E, Tschachler, and R, Strohal
- Subjects
AIDS-Related Opportunistic Infections ,Risk Factors ,Dentistry ,Oral Medicine ,HIV-1 ,Humans ,HIV Infections ,Orthodontics ,Mouth Diseases - Published
- 1997
21. Letter to the Editor
- Author
-
C. Schiessl and R. Strohal
- Subjects
Immunology and Allergy ,Dermatology - Published
- 2004
22. T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin
- Author
-
R, Strohal, L, Paucz, H, Pehamberger, and G, Stingl
- Subjects
Adult ,Male ,Skin Neoplasms ,Base Sequence ,Receptors, Antigen, T-Cell, alpha-beta ,T-Lymphocytes ,Molecular Sequence Data ,Middle Aged ,Polymerase Chain Reaction ,Neoplasm Proteins ,Lymphocytes, Tumor-Infiltrating ,Phenotype ,Antigens, Neoplasm ,CD4 Antigens ,Humans ,Female ,Melanoma ,Melanoma-Specific Antigens ,Aged ,Skin - Abstract
Lymphocytes infiltrating solid tumors can be propagated in vitro with interleukin 2 and are then capable, as CD8+ cytotoxic T-cells, of specific lysis of autologous tumor targets in a class I-restricted manner. Since the specificity of these cells is determined by their T-cell receptor (TCR) configuration, the aim of this study was to delineate the TCR V alpha repertoire of tumor-infiltrating lymphocytes within 24 melanoma specimens and to compare these data with the TCR expression pattern of unaffected peritumoral and normal human skin. While lymphocytes within all skin specimens tested expressed a substantial, albeit limited, heterogeneity of V alpha specificities with an average number of 9.0 different V alpha gene segments, the V alpha repertoire within cutaneous melanoma lesions was significantly more restricted (mean of V alpha expression, 3.86; P0.001) with a predominance of only 3 V alpha families (V alpha 13, V alpha 15, and V alpha 16), all of which were also found to be expressed within normal skin. Collectively, the fact that the TCR V alpha repertoire in melanoma is skewed toward the predominance of only a few V alpha regions may be indicative of a limited number of melanoma-associated antigenic determinants being involved in the anti-tumor immune response.
- Published
- 1994
23. The role of fetal epithelial tissues in the maturation/differentiation of bone marrow-derived precursors into dendritic epidermal T cells (DETC) of the mouse
- Author
-
G, Stingl, A, Elbe, E, Paer, O, Kilgus, R, Strohal, and S, Schreiber
- Subjects
Mice ,Fetus ,T-Lymphocyte Subsets ,Animals ,Cell Differentiation ,Receptors, Antigen, T-Cell, gamma-delta ,Dendritic Cells ,Hematopoietic Stem Cells ,Skin - Abstract
Our attempts to clarify the contribution of the thymic vs. the cutaneous microenvironment in the maturation of dendritic epidermal T cell (DETC) precursors into DETC gave diverse results. In one series of experiments, we found that i.v. injection of fetal thymocytes (containing a TCR V gamma 3-expressing subpopulation), but not of adult thymocytes (containing no TCR V gamma 3+ cells) results in the appearance of CD3/TCR V gamma 3+ dendritic epidermal cells (=DETC). In other experiments, we have obtained evidence that transplantation of day 16 fetal skin onto a Thy-1-disparate recipient results in the appearance of donor-type DETC. Our further observation that the transplanted skin contains CD45+/Thy-1+/CD3- lymphocytes, but no mature T cells, therefore implies that fetal skin can provide stimuli promoting the expression of CD3/TCR genes in immature (CD3-) DETC precursors. It remains to be seen whether both or only one of these maturational pathways are (is) followed under physiological conditions.
- Published
- 1991
24. Homoeopathic Preparations – Severe Adverse Effects, Unproven Benefits
- Author
-
R. Strohal and W. Aberer
- Subjects
medicine.medical_specialty ,business.industry ,Pruritus ,medicine ,Alternative medicine ,Humans ,Homeopathy ,Dermatology ,Adverse effect ,business ,Anaphylaxis - Published
- 1991
25. Immunoglobulin kappa light chain variable region gene complex organization and immunoglobulin genes encoding anti-DNA autoantibodies in lupus mice
- Author
-
M A Duchosal, Frank J. Dixon, R. Strohal, Argyrios N. Theofilopoulos, R Kofler, Robert S. Balderas, Daniel J. Noonan, and M.E. Johnson
- Subjects
Molecular Sequence Data ,Immunoglobulin Variable Region ,Biology ,Immunoglobulin light chain ,Immunoglobulin kappa-Chains ,Mice ,Mice, Inbred AKR ,medicine ,Animals ,Lupus Erythematosus, Systemic ,Amino Acid Sequence ,Gene ,Genetics ,Mice, Inbred C3H ,Systemic lupus erythematosus ,Base Sequence ,Genes, Immunoglobulin ,Mice, Inbred NZB ,Haplotype ,Antibody Diversity ,DNA ,General Medicine ,medicine.disease ,Molecular biology ,Mice, Inbred C57BL ,Genes ,Antibodies, Antinuclear ,biology.protein ,Immunoglobulin heavy chain ,Female ,Restriction fragment length polymorphism ,Antibody ,Immunoglobulin Heavy Chains ,Research Article - Abstract
We have investigated the genetic origin of autoantibody production in several strains of mice that spontaneously develop a systemic lupus erythematosus-like disease. Restriction fragment length polymorphism analyses of gene loci encoding kappa light chain variable regions (Igk-V) demonstrated, as shown previously for the Ig heavy chain locus, that autoantibody production and disease occur in different Igk-V haplotypes. Moreover, autoimmune mice with known genetic derivation inherited their Igk-V loci essentially unaltered from their nonautoimmune ancestors. New Zealand black lupus mice, with unknown genetic derivation, had a possibly recombinant Igk-V haplotype, composed of V kappa loci that were primarily indistinguishable from those of nonautoimmune strains from either of the two potential donor haplotypes. The heavy and light chain gene segments (variable, diversity, joining) encoding anti-DNA antibodies were diverse and often closely related, or even identical, to those found in antibodies to foreign antigens in normal mice. Only 1 of 11 sequenced variable region genes could not be assigned to existing variable region gene families; however, corresponding germline genes were present in the genome of normal mice as well. These data argue against abnormalities in the genes and mechanisms generating antibody diversity in lupus mice and suggest a remarkable genetic and structural diversity in the generation of anti-DNA binding sites.
- Published
- 1988
26. The genetic origin of murine lupus-associated autoantibodies
- Author
-
R Kofler, G. Krömer, R. Fässler, M.T. Aguado, M.E. Johnson, R. Strohal, and M A Duchosal
- Subjects
Genetics ,Systemic lupus erythematosus ,Somatic cell ,Immunology ,Autoantibody ,Immunoglobulins ,Biology ,medicine.disease ,Germline ,Mice ,Germline mutation ,Antigen ,Mutation ,medicine ,biology.protein ,Immunology and Allergy ,Animals ,Humans ,Lupus Erythematosus, Systemic ,Antibody ,Gene ,Antibody Diversity ,Autoantibodies - Abstract
Systemic lupus erythematosus and rheumatoid arthritis in human and murine systems are characterized by circulating autoantibodies and immune complex deposition in various organs causing tissue damage and disease. To define the molecular and clonotypic origin of these anti-self responses, and to determine whether abnormalities in Ig genes or somatic mechanisms generating autoantibody diversity may contribute to lupus etiology, we performed molecular analyses of the Ig germline gene organization and the Ig gene segments expressed in monoclonal autoantibodies from autoimmune mice. Comparative restriction fragment length polymorphism analysis of a large number of Ig gene loci from autoimmune and normal mice indicated that (a) lupus can develop in different Ig heavy and kappa light chain variable region gene haplotypes, and (b) the Ig germline genes in lupus mice might be normal. To determine whether autoantibodies are encoded by unique Ig gene segments present in the normal germline repertoire, but not expressed in exogenous responses, we compared nucleic acid sequences encoding lupus autoantibodies and antibodies against foreign antigens. Similar, and in some instances even identical, gene segments were expressed in both types of antibodies, indicating that anti-self and anti-foreign responses use the same, or at least an overlapping, germline gene repertoire. A large variety of Ig variable, diversity, and joining gene segments encoded these autoantibodies with different specificities. Hence, the overall murine lupus-associated anti-self response may be essentially unrestricted. Furthermore, limited evidence has been obtained that both germline genes and somatically mutated genes encode autospecificity, making gross abnormalities in mechanisms for somatic mutation of Ig variable genes unlikely. Based on the studies performed thus far, the general principles governing murine lupus-associated anti-self responses and responses against exogenous antigens appear to be the same.
- Published
- 1987
27. Cloning and Sequencing of Murine Lupus-Associated Autoantibody Genes
- Author
-
A. N. Theofilopoulos, Reinhard Faessler, R. Strohal, F. J. Dixon, G. Wick, Daniel J. Noonan, Guido Kroemer, and R. Kofler
- Subjects
Germline mutation ,Systemic lupus erythematosus ,Haplotype ,medicine ,biology.protein ,Antibody Diversity ,Restriction fragment length polymorphism ,Biology ,Antibody ,medicine.disease ,Gene ,Molecular biology ,Germline - Abstract
Immunoglobulin (Ig) heavy (H) and light (L) chain variable (V) region genes are assembled somatically during B-cell differentiation by stage-specific DNA rearrangements of multiple V, diversity (D, H chains only), and joining (J) germline gene segments (reviewed by Alt et al, 1986). Different combinations and imprecise joining of V, D and J elements, random insertion of nucleotides during the joining process (N regions), as well as somatic mutation, contribute to the generation of antibody diversity and ultimately determine the specificity (self or non-self antigen) of a given antibody. Murine lupus is characterised by high titres of circulating autoantibodies (AAb) leading to immune complex mediated lesions (Theofilopoulos and Dixon, 1985). We have previously shown, by means of restriction fragment length polymorphism analysis, that lupus mice and non-lupus mice of the same haplotypes share highly conserved H chain variable region loci (Kofler et al., 1985b). In the present study, we report a detailed analysis of nucleotide sequences corresponding to H and L chains of nine monoclonal AAb with different specificities frequently expressed during lupus disease (single stranded DNA, histone and various Ig isotypes). The following questions were addressed: Arc there any primary structures common to ail AAb regardless of their specificity, which might signal their autoreactive nature? Do AAb employ Ig genes in a restricted manner and are there unique Ig genes different from the germline pool used in the response to exogenous antigens? To what extent is self-specificity germline encoded or acquired during B-cell development?
- Published
- 1988
28. [Molecular genetic analysis of autoantibody production in systemic lupus erythematosus]
- Author
-
R, Strohal, G, Krömer, H, Wolf, G, Wick, and R, Kofler
- Subjects
Mice ,Gene Expression Regulation ,Animals ,Humans ,Immunoglobulins ,Lupus Erythematosus, Systemic ,DNA ,Cloning, Molecular ,Polymorphism, Restriction Fragment Length ,Autoantibodies - Abstract
This review summarizes studies from our and other laboratories attempting to define the molecular and clonotypic origin of autoantibodies that typify systemic autoimmune diseases such as lupus and rheumatoid arthritis. Comparative restriction fragment length polymorphism (RFLP) studies investigating the immunoglobulin (Ig) germline gene organization in lupus-prone strains of mice suggested that the disease can develop in different Ig heavy (H) and light (L) chain haplotypes, and that the Ig germline genes in lupus mice are probably normal. Analysis of the Ig gene segments expressed in monoclonal autoantibodies from autoimmune mice revealed that similar, and in some instances even identical, gene segments are expressed in autoantibodies and in antibodies to exogenous antigens, and that anti-self and anti-non-self responses are encoded by the same, or at least an overlapping germline gene repertoire. A large variety of Ig variable (V), diversity (D), and joining (J) gene segments can encode autoantibodies with different specificities, and both germline genes and somatically-mutated genes can be expressed in such antibodies.
- Published
- 1988
29. [Manual therapy of static disorders of the foot]
- Author
-
R, STROHAL
- Subjects
Foot Diseases ,Foot ,Humans ,Musculoskeletal Manipulations ,Chiropractic - Published
- 1958
30. [Aspects on the statics of the spine]
- Author
-
R, STROHAL
- Subjects
Neurites ,Humans ,Spine - Published
- 1957
31. Complete variable region sequence of a nonfunctionally rearranged kappa light chain transcribed in the nonsecretor P3-X63-Ag8.653 myeloma cell line
- Author
-
R Kofler, G. Wick, Guido Kroemer, and R Strohal
- Subjects
Genetics ,Mice, Inbred BALB C ,Base Sequence ,Transcription, Genetic ,Protein primary structure ,Immunoglobulin Variable Region ,Gene rearrangement ,Biology ,medicine.disease ,Immunoglobulin light chain ,Cell Line ,Immunoglobulin kappa-Chains ,Mice ,Genes ,medicine ,biology.protein ,Plasmacytoma ,Animals ,Immunoglobulin Light Chains ,Line (text file) ,Antibody ,Gene ,Sequence (medicine)
32. Evidence for a new murine immunoglobulin heavy chain variable region gene family
- Author
-
R Strohal, Reinhard Kofler, Reinhard Faessler, Georg Wick, and Guido Kroemer
- Subjects
Transcription, Genetic ,Immunology ,Immunoglobulin Variable Region ,Mice, Inbred Strains ,Biology ,Mice ,Complementary DNA ,medicine ,Gene family ,Animals ,B cell ,Sequence (medicine) ,Autoantibodies ,Genetics ,Base Sequence ,Autoantibody ,Nucleic acid sequence ,General Medicine ,Molecular biology ,Clone Cells ,medicine.anatomical_structure ,Genetic Code ,biology.protein ,Immunoglobulin heavy chain ,Antibody ,Immunoglobulin Heavy Chains ,Polymorphism, Restriction Fragment Length - Abstract
In the course of a previous study addressing autoantibody generation in murine models for generalized autoimmune disorders, we observed a nonfunctional immunoglobulin heavy chain transcript in a B cell hybridoma from lupus-prone MRL-Mp-lpr/lpr mice. This transcript, the cDNA sequence of which is presented here, is of general interest for murine immunoglobulin genetics as it cannot be ascribed to any known heavy chain variable region gene (Vh) family by nucleic acid sequence homology criteria and, hence, may represent a new Vh gene family. The sequence showed about equal nucleotide similarity (70-73%) to 3 other Vh gene families (S107, J606, 7183) and less than 65% similarity to members of the remaining 6 Vh gene families. Nucleic acid sequence comparisons with unpublished immunoglobulin sequences uncovered a highly homologous (greater than 95%) functional Vh transcript indicating that the suggested Vh gene family also encodes expressed antibody molecules.
33. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
- Author
-
Strober B, Bachelez H, Crowley J, Elewski BE, Gooderham M, Menter A, Strohal R, Chen MM, Wu T, Zhan T, Photowala H, and Armstrong A
- Subjects
- Humans, Male, Female, Middle Aged, Double-Blind Method, Adult, Antibodies, Monoclonal therapeutic use, Nail Diseases drug therapy, Treatment Outcome, Dermatologic Agents therapeutic use, Psoriasis drug therapy, Psoriasis complications, Severity of Illness Index
- Abstract
Background: Psoriasis is an inflammatory skin disease that impacts a heterogeneous group of patients and can have multiple clinical manifestations. Risankizumab is approved for the treatment of moderate-to-severe plaque psoriasis., Objectives: To evaluate the long-term efficacy of risankizumab according to baseline patient characteristics, and for the treatment of high-impact disease manifestations (nail, scalp and palmoplantar psoriasis), through 256 weeks of continuous treatment in the phase 3 LIMMitless study., Methods: This subgroup analysis evaluated pooled data from patients with moderate-to-severe plaque psoriasis who were randomized to risankizumab 150 mg during two double-blind, phase 3, 52-week base studies (UltIMMa-1/2; NCT02684370/NCT02684357) and were enrolled in the phase 3 LIMMitless open-label extension study (NCT03047395). Subgroup assessments included the proportion of patients who achieved ≥90%/100% improvement in Psoriasis Area and Severity Index (PASI 90/100). Among patients with nail, scalp and/or palmoplantar psoriasis in addition to skin psoriasis, assessments included changes from baseline in and resolution of these three psoriatic manifestations., Results: Overall, a numerically similar proportion of patients (N = 525) achieved PASI 90/100 through Week 256, regardless of their baseline age, sex, body mass index, weight, PASI or psoriatic arthritis status. Patients with nail, scalp and/or palmoplantar psoriasis experienced substantial improvements in manifestation-specific indices (mean improvement from baseline to Week 256 of >81%, >94% and >97%, respectively); in patients with all three manifestations (N = 121), 44.6% achieved complete clearance of these manifestations at Week 256., Conclusions: Risankizumab demonstrated generally consistent efficacy through 256 weeks across patient subgroups and showed durable long-term efficacy for psoriatic disease manifestations., (© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
34. [M.O.I.S.T. concept for the local therapy of chronic wounds].
- Author
-
Dissemond J, Assenheimer B, Gerber V, Kurz P, Läuchli S, Panfil EM, Probst S, Traber J, and Strohal R
- Subjects
- Humans, Wound Healing, Wounds and Injuries
- Abstract
The treatment of patients with chronic wounds is still an interdisciplinary and interprofessional challenge. The basis of successful therapy for these patients is based on causal treatment of the underlying, pathophysiologically relevant diseases. In addition, however, local wound therapy should always be provided to support wound healing and avoid complications. In order to better structure the multitude of wound products, the M.O.I.S.T. concept was developed by a multidisciplinary expert group of WundDACH, the umbrella organization of German-speaking professional societies. M describes, O oxygenation, I infection control, S support of the healing process and T tissue management.The M.O.I.S.T. concept is intended to provide healthcare professionals a guidance for systematic planning and also for education with regard to the local therapy of patients with chronic wounds. The 2022 update of this concept is now presented here for the first time., Competing Interests: Joachim Dissemond: Honorare für Vorträge, Beratungen oder Studien von folgenden Firmen: 3M, B. Braun, Biomonde, Curea, Coloplast, Convatec, Draco, Engelhardt, Flen Pharma, Hartmann, Infectopharm, Lohmann&Rauscher, Mölnlycke, Piomic, Uluru, UPM, Urgo. Bernd Assenheimer: keine. Veronika Gerber: keine. Peter Kurz: Honorare für Vorträge, Beratungen oder Studien von folgenden Firmen erhalten: Accelheal, Arjo, B. Braun, Coloplast, Convatec, Hartmann, Mölnlycke, Terraplasma, Urgo. Severin Läuchli: Honorare für Vorträge, Beratungen oder Studien von folgenden Firmen: Abbvie, Galderma, Hartmann, Kerecis, MiMedx, MSD, Novartis, Sandoz, Sanofi, Urgo. Eva Maria Panfil: keine. Sebastian Probst: Honorare für Vorträge, Beratungen oder Studien von folgenden Firmen erhalten: Curea, Convatec, Mölnlycke, Integra, Hartmann. Jürg Traber: Honorare für Beratungen von folgenden Firmen: Urgo, Piomic. Robert Strohal: keine., (Thieme. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
35. Author Correction: Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trial.
- Author
-
Strohal R, Dietrich S, Mittlböck M, and Hämmerle G
- Published
- 2022
- Full Text
- View/download PDF
36. Chronic wounds treated with cold atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized, non-inferiority trial.
- Author
-
Strohal R, Dietrich S, Mittlböck M, and Hämmerle G
- Subjects
- Humans, Prospective Studies, Bandages, Wound Healing
- Abstract
The use of phase-adapted wound dressings represents best practice (BP) in chronic wound treatment. However, efficacy is often limited and associated care requirements are high. Cold atmospheric plasmajet (CAP-jet) is a promising new therapeutic tool for these wounds. In the present multicenter, randomized, open-label, prospective, clinical trial, non-inferiority of the CAP-jet versus BP was assessed in 78 patients with infected or non-infected chronic wounds of different etiology. Primary outcome measure was the sum of granulation tissue, furthermore wound area reduction, healing rate, time to complete healing, changes in wound pH value, infection score, exudate level and local tolerability were assessed. In CAP-jet treated wounds compared to control, the sum of granulation tissue was significantly higher (p < 0.0001) and wound area reduced significantly faster (p < 0.001). Furthermore, wound pH value decreased significantly faster (p = 0.0123) and local infection was overcome more rapidly by CAP-jet therapy. In 58.97% CAP-jet- vs. 5.13% BP-treated patients, complete healing of chronic ulcers was documented after 6 weeks. Treatment with CAP-jet appeared not only non-inferior, but even superior to BP in all wound entities analyzed with a favorable tolerability profile. Thus, treatment with the CAP-jet provides beneficial effects in chronic wound treatment regarding promotion of the wound healing process., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
37. Management of hard-to-heal leg ulcers with an acid-oxidising solution versus standard of care: the MACAN study.
- Author
-
Strohal R, Mittlböck M, Müller W, and Hämmerle G
- Subjects
- Bandages, Humans, Treatment Outcome, Wound Healing, Leg Ulcer therapy, Standard of Care
- Abstract
Objective: The efficacy of available wound dressings in the treatment of hard-to-heal wounds is limited. A new therapeutic approach using an acid-oxidising solution (AOS) was developed. Its effect on healing progress, tolerability and safety properties were investigated in a clinical study, and compared with standard of care (SOC) wound dressings. The study aimed to demonstrate the non-inferiority of AOS to SOC in terms of wound healing progress., Method: This open-label, randomised controlled trial was conducted at two study centres in Austria with patients with either infected or non-infected hard-to-heal leg ulcers of different aetiology. Patients were treated for six weeks either with AOS or SOC wound dressings. Outcome assessments included the percentage of granulation and re-epithelialisation tissue, wound size reduction, changes in wound pH, infection control and wound pain, local tolerability and adverse events (AEs). Healing time and rate were also assessed., Results: A total of 50 patients took part. In the AOS group, wounds exhibited higher amounts of granulation and re-epithelialisation tissue, and a faster and more pronounced wound size reduction compared with wounds in the SOC group. In the AOS-treated versus SOC-treated patients, a greater percentage of complete healing of hard-to-heal ulcers was achieved by the end of the study period (32% versus 8%, respectively). Furthermore, the wound pH decreased significantly faster in these wounds (p<0.0001). In all patients with infected leg ulcers, local infection was overcome more rapidly under AOS treatment. In the AOS group, one AE and no serious adverse events (SAEs) were detected versus 24 AEs and two SAEs in the SOC group., Conclusion: In this study, AOS proved to be a highly effective treatment to support wound healing in infected or non-infected hard-to-heal leg ulcers of different aetiology. Efficacy was found to be not only non-inferior but superior to SOC wound dressings. Furthermore, tolerability and safety profiles were favourable for AOS.
- Published
- 2021
- Full Text
- View/download PDF
38. Flüssigkeits-assoziierte Hautschäden (FAH): Eine Best Practice Empfehlung von Wund-D.A.CH.
- Author
-
Dissemond J, Assenheimer B, Gerber V, Hintner M, Puntigam MJ, Kolbig N, Koller S, Kurz P, Läuchli S, Probst S, Protz K, Steiniger A, Strohal R, Traber J, and Kottner J
- Published
- 2021
- Full Text
- View/download PDF
39. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
- Author
-
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, Sator PG, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Painsi C, Selhofer S, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Tanew A, Inzinger M, Tatarski R, Bangert C, Ellersdorfer C, Lichem R, Gruber-Wackernagel A, Hofer A, Legat F, Schmiedberger E, Strohal R, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hoetzenecker W, Trautinger F, Saxinger W, Müllegger R, Quehenberger F, and Wolf P
- Subjects
- Adalimumab, Austria, Cohort Studies, Etanercept, Female, Humans, Registries, Retrospective Studies, Survival Rate, Treatment Outcome, Ustekinumab, Biological Products, Psoriasis drug therapy
- Abstract
Background: Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time-dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options., Objectives: To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment., Methods: This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019., Results: A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long-term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non-naïvety (2·10, P < 0·001), the introduction of a new drug such as secukinumab or ixekizumab (relative hazard ratio 1·6, P = 0·001) and female gender (1·50, P = 0·019) increased the risk of treatment discontinuation overall, whereas psoriatic arthritis did not (1·12, P = 0·21)., Conclusions: The time-dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment., (© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
- Published
- 2021
- Full Text
- View/download PDF
40. Moisture-associated skin damage (MASD): A best practice recommendation from Wund-D.A.CH.
- Author
-
Dissemond J, Assenheimer B, Gerber V, Hintner M, Puntigam MJ, Kolbig N, Koller S, Kurz P, Läuchli S, Probst S, Protz K, Steiniger A, Strohal R, Traber J, and Kottner J
- Subjects
- Humans, Skin, Skin Care, Dermatitis, Fecal Incontinence, Skin Diseases
- Abstract
Wund-D.A.CH., as the umbrella organization of German-speaking wound treatment societies, has currently developed a best practice recommendation for skin damage caused by body fluids, which is known as moisture-associated skin damage (MASD) in English-speaking countries. In this expert consensus, the diseases incontinence-associated dermatitis (IAD), intertriginous dermatitis, including intertrigo, gram-negative bacterial toe web infection and toxic contact dermatitis, including periwound and peristomal dermatitis are presented in a differentiated manner. A common feature of these clinical diseases is a deterioration of skin integrity due to prolonged exposure to body fluids such as urine, stool, sweat or wound exudate with associated physical-irritative and/or chemical irritation. In addition, other comorbidities and cofactors play an important role. The diagnosis of these interdisciplinary and interprofessionally relevant MASD is difficult in everyday clinical practice because there are currently no uniform definitions and many relevant differential diagnoses. Effective strategies for the prevention and therapy of these skin diseases are, for example, continence management, use of efficient, absorbent aids with good retention as well as consistent skin protection and adequate skin care. Another important aspect is the education of patients and relatives about the origin, treatment and prevention of MASD., (© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.)
- Published
- 2021
- Full Text
- View/download PDF
41. Therapeutic Index for Local Infections score validity: a retrospective European analysis.
- Author
-
Dissemond J, Strohal R, Mastronicola D, Senneville E, Moisan C, Edward-Jones V, Mahoney K, Junka A, Bartoszewicz M, and Verdú-Soriano J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Europe, Female, Humans, Male, Middle Aged, Reproducibility of Results, Retrospective Studies, Young Adult, Anti-Infective Agents, Local therapeutic use, Leg Ulcer drug therapy, Therapeutic Index, Wound Infection drug therapy
- Abstract
Objective: A score to identify local wound infections was developed by a panel of experts from seven European countries. The Therapeutic Index for Local Infections (TILI) score was designed for health professionals who are not specialised in wound care. This study was carried out to test the validity of the TILI score in everyday practice., Method: Content validity was analysed by means of evaluation by a panel of experts, individually and face-to-face, followed by a European multicentred, retrospective, observational study. Participating clinicians sent anonymised copies of completed TILI scores for patients with leg ulcers along with a photograph of the wound for analysis by two blinded reviewers. Concordance (Kappa index) and convergent criterion validity (sensitivity, specificity, accuracy, Youden's J Index and receiver operator characteristic (ROC) or area under the curve (AUC) curve) were calculated to construct validity and reliability., Results: A total of 307 patients with leg ulcers from seven institutions in five European countries were included in this retrospective analysis. It was shown that the diagnosis of local wound infection could be documented well with five of the six clinical criteria included in the TILI score. By summing up these facultative criteria in comparison with any direct criteria that may be present, there would have been an indication for local antiseptic wound therapy in 22% of patients examined., Conclusions: The results show that the TILI score is concordant with the expert assessment of patients and with good diagnostic characteristics. Thus, the easy-to-use TILI score can now be used in the daily routine practice of health professionals to diagnose local wound infections.
- Published
- 2020
- Full Text
- View/download PDF
42. Therapeutic index for local infections score (TILI): a new diagnostic tool.
- Author
-
Dissemond J, Gerber V, Lobmann R, Kramer A, Mastronicola D, Senneville E, Moisan C, Edwards-Jones V, Mahoney K, Junka A, Bartoszewicz M, Verdú-Soriano J, and Strohal R
- Subjects
- Humans, Wound Infection diagnosis, Therapeutic Index, Wound Infection therapy
- Abstract
Objective: Local wound infections are a major challenge for patients and health professionals. Various diagnostic and therapeutic options are available. However, a generally accepted standard is still lacking in Europe. The aim was to develop an easy-to-use clinical score for the early detection of local wound infections, as a basis for decision-making on antiseptic therapy or decolonisation., Method: An interdisciplinary and interprofessional panel of experts from seven European countries was brought together to discuss the various aspects of diagnosing local wound infections., Results: The result was the adoption of the Therapeutic Index for Local Infections (TILI) score, developed in Germany by Initiative Chronische Wunden e.V., specifically for health professionals not specialised in wound care. Available in six European languages, the TILI score could also be adapted for different European countries, depending on their specific national healthcare requirements. The six clinical criteria for local wound infection are erythema to surrounding skin; heat; oedema, induration or swelling; spontaneous pain or pressure pain; stalled wound healing; and increase and/or change in colour or smell of exudate. Meeting all criteria indicates that antiseptic wound therapy could be started. Regardless of these unspecific clinical signs, there are also health conditions for the clinical situation which are a direct indication for antimicrobial wound therapy. These include the presence of wound pathogens, such as meticillin-resistant Staphylococcus aureus , septic surgical wound or the presence of free pus., Conclusion: The development of the new internationally adapted TILI score, which could also be used by any caregiver in daily practice to diagnose local infections in acute and hard-to-heal wounds, is the result of expert consensus. However, the score system has to be validated through a clinical evaluation. This is to be performed in expert centres throughout Europe.
- Published
- 2020
- Full Text
- View/download PDF
43. [Sucrose octasulfate-evidence in the treatment of chronic wounds].
- Author
-
Dissemond J, Augustin M, Dietlein M, Keuthage W, Läuchli S, Lobmann R, Münter KC, Stücker M, Traber J, Vanscheidt W, and Strohal R
- Subjects
- Anti-Ulcer Agents pharmacology, Humans, Sucrose pharmacology, Sucrose therapeutic use, Wound Healing, Anti-Ulcer Agents therapeutic use, Sucrose analogs & derivatives, Varicose Ulcer drug therapy
- Abstract
Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was a double-blind RCT with 187 patients with VLU. The SPID study was a pilot study with 33 patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88 patients with VLU in different phases of healing. In the REALITY study, a pooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, a significant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.
- Published
- 2020
- Full Text
- View/download PDF
44. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review.
- Author
-
Dissemond J, Augustin M, Dietlein M, Faust U, Keuthage W, Lobmann R, Münter KC, Strohal R, Stücker M, Traber J, Vanscheidt W, and Läuchli S
- Subjects
- Bandages, Cellulose, Cellulose, Oxidized, Chronic Disease, Colloids therapeutic use, Diabetic Foot therapy, Humans, Matrix Metalloproteinases, Pressure Ulcer therapy, Randomized Controlled Trials as Topic, Time Factors, Varicose Ulcer therapy, Bandages, Hydrocolloid, Matrix Metalloproteinase Inhibitors therapeutic use, Oligosaccharides therapeutic use, Wound Healing, Wounds and Injuries therapy
- Abstract
Objective: Matrix metalloproteinases (MMPs) substantially contribute to the development of chronicity in wounds. Thus, MMP-inhibiting dressings may support healing. A systematic review was performed to determine the existing evidence base for the treatment of hard-to-heal wounds with these dressings., Methods: A systematic literature search in databases and clinical trial registers was conducted to identify randomised controlled trials (RCTs) investigating the efficacy of MMP-inhibiting dressings. Studies were analysed regarding their quality and clinical evidence., Results: Of 721 hits, 16 relevant studies were assessed. There were 13 studies performed with collagen and three with technology lipido-colloid nano oligosaccharide factor (TLC-NOSF) dressings. Indications included diabetic foot ulcers, venous leg ulcers, pressure ulcers or wounds of mixed origin. Patient-relevant endpoints comprised wound size reduction, complete wound closure, healing time and rate. Considerable differences in the quality and subsequent clinical evidence exist between the studies identified. Substantial evidence for significant improvement in healing was identified only for some dressings., Conclusion: Evidence for the superiority of some MMP-inhibiting wound dressings exists regarding wound closure, wound size reduction, healing time and healing rate. More research is required to substantiate the existing evidence for different types of hard-to-heal wounds and to generate evidence for some of the different types of MMP-inhibiting wound dressings.
- Published
- 2020
- Full Text
- View/download PDF
45. Neues aus der Union of European Medical Specialists (UEMS).
- Author
-
Strohal R and Längle U
- Published
- 2019
- Full Text
- View/download PDF
46. Knowledge and Influence of Predatory Journals in Dermatology: A Pan-Austrian Survey.
- Author
-
Richtig G, Richtig M, Hoetzenecker W, Saxinger W, Lange-Asschenfeldt B, Steiner A, Strohal R, Posch C, Bauer JW, Müllegger RR, Deinlein T, Sepp N, Volc-Platzer B, Nguyen VA, Schmuth M, Hoeller C, Pregartner G, and Richtig E
- Subjects
- Adult, Austria, Clinical Decision-Making, Female, Humans, Male, Middle Aged, Prospective Studies, Scientific Misconduct, Attitude of Health Personnel, Dermatologists psychology, Health Knowledge, Attitudes, Practice, Open Access Publishing economics, Open Access Publishing ethics, Periodicals as Topic economics, Periodicals as Topic ethics
- Abstract
The aim of this study was to assess the knowledge and influence of predatory journals in the field of dermatology in Austria. A total of 286 physicians (50.5% men) completed a questionnaire. The vast majority of subjects read scientific articles (n = 281, 98.3%) and took them into consideration in their clinical decision-making (n = 271, 98.5% of participants that regularly read scientific literature). Open access was known by 161 (56.3%), predatory journals by 84 (29.4%), and the Beall's list by 19 physicians (6.7%). A total of 117 participants (40.9%) had been challenged by patients with results from the scientific literature, including 9 predatory papers. Participants who knew of predatory journals had a higher level of education as well as scientific experience, and were more familiar with the open-access system (p < 0.001). These results indicate that the majority of dermatologists are not familiar with predatory journals. This is particularly the case for physicians in training and in the early stages of their career.
- Published
- 2019
- Full Text
- View/download PDF
47. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey.
- Author
-
Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange-Asschenfeldt B, Trautinger F, Mlynek A, Strohal R, Augustin M, and Quehenberger F
- Subjects
- Austria, Cross-Sectional Studies, Humans, Pain, Pruritus, Quality of Life, Psoriasis complications, Psoriasis therapy
- Abstract
Background: Patients with psoriasis experience impairment in quality of life. Thus, high-quality dermatological care is of particular importance., Patients and Methods: We performed a nationwide cross-sectional survey in Austria (BQSAustria Psoriasis 2014/2015) with a special focus on quality of life and satisfaction with treatment among psoriasis patients predominantly treated at tertiary care centers., Results: Overall, 70.2 % of 1,184 patients reported impaired quality of life (DLQI 2-5: 29.4 %; 6-10: 19.3 %; 11-15: 11.5 %; 16-20: 5.2 % and > 20: 4.9 %) despite treatment over the preceding four weeks (topical treatment in 88.2 % of cases and/or systemic treatment in 38.7 %). On average, none of the 25 defined subjective treatment goals was achieved to a sufficient degree. In particular, 82.2 % of patients continued to have pruritus despite treatment, which was highly significantly associated with a poor general health status over the preceding week (Spearman's rank correlation; p = 1.1e-45), the extent of body surface area (p = 3.2e-11) and scalp area (p = 3.2e-11) affected, as well as pain (p = 2.3e-22). Treatment with a biologic was significantly correlated with higher patient satisfaction (Wilcoxon-Test, p = 2.0e-16)., Conclusions: Despite dermatological care, the majority of Austrian psoriasis patients continues to experience impaired quality of life; there is potential for improvement in the achievement of treatment goals., (© 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
48. Lebensqualität und Behandlungsziele bei Psoriasis aus Patientensicht: Ergebnisse eines österreichweiten Querschnitt-Survey.
- Author
-
Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange-Asschenfeldt B, Trautinger F, Mlynek A, Strohal R, Augustin M, and Quehenberger F
- Abstract
Hintergrund: Patienten mit Psoriasis sind mit einer krankheitsbedingten Einschränkung ihrer Lebensqualität konfrontiert, weshalb einer hochqualitativen dermatologischen Versorgung ein besonderer Stellenwert zukommt., Patienten Und Methodik: Wir führten einen bundesweiten Querschnitt-Survey in Österreich (BQSAustria Psoriasis 2014/2015) mit dem Schwerpunkt auf Lebensqualität und Therapiezufriedenheit bei Patienten mit Psoriasis in dermatologischer Behandlung vorwiegend an Zentren mit überwiegend tertiären Versorgungsaufgaben durch., Ergebnisse: 70,2 % der 1184 befragten Patienten berichtete über eine eingeschränkte Lebensqualität (DLQI 2-5: 29,4 %; 6-10: 19,3 %; 11-15: 11,5 %; 16-20: 5,2 % und > 20: 4,9 %) trotz Behandlung innerhalb der letzten vier Wochen (mit lokaler Therapie in 88,2 % und/oder systemischer Therapie in 38,7 % der Fälle). Mit den verabreichten Therapien konnte im Durchschnitt kein einziges von 25 definierten subjektiven Behandlungszielen im gewünschten Ausmaß erreicht werden. So litten 82,2 % der Patienten trotz Behandlung weiter unter Juckreiz, wobei statistisch hochsignifikante Assoziationen mit einem schlechten Gesundheitszustand in der letzten Woche (Spear-man-Rangkorrelation; p = 1.1e-45), dem Ausmaß des psoriatischen Körperoberflächenbefalls (p = 3.2e-11) und Kopfhautbefalls (p = 3.2e-11) sowie Schmerzen (p = 2.3e-22) vorlagen. Die Behandlung mit einem Biologikum war mit einer signifikant höheren Patientenzufriedenheit verbunden (Wilcoxon-Test, p = 2.0e-16)., Schlussfolgerungen: Die Lebensqualität der meisten österreichischen Patienten mit Psoriasis in dermatologischer Versorgung ist krankheitsbedingt beeinträchtigt, und es besteht ein Verbesserungspotenzial bei der Umsetzung von Behandlungszielen., (© 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
49. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
- Author
-
Carrascosa JM, Jacobs I, Petersel D, and Strohal R
- Abstract
Psoriasis is a chronic, inflammatory, lifelong disease with a high prevalence (afflicting approximately 1-5% of the population worldwide) and is associated with significant morbidity. The introduction of biologic therapies has improved the management of this disease. Multiple biologic medicines that block cytokine signaling, including tumor necrosis factor (TNF) antagonists (adalimumab, etanercept, and infliximab) and inhibitors of interleukin (IL)-17 (brodalumab, ixekizumab, and secukinumab), IL-23 (guselkumab), or IL-12/23 (ustekinumab), are approved for the treatment of psoriasis. Despite the clinical benefits associated with use of biologics in psoriasis, many patients are not treated with biologic therapy, and access to treatment may be limited for various reasons, such as high treatment costs. Patents for many biologics have expired or will soon expire, and biosimilar versions of these agents are available or in development. A biosimilar is a biological product that is highly similar to an approved biologic (i.e., originator or reference) product, and has no clinically meaningful differences in safety, purity, or potency when compared with the reference product. Biosimilars may offer less expensive treatment options for patients with psoriasis; they also may increase access to and address problems with underutilization of biologic therapy. Biosimilar development and approval follows a well-regulated process in many countries, with guidelines developed by the European Medicines Agency, US Food and Drug Administration, and World Health Organization. Currently, several anti-TNF biosimilars are available for use in patients with psoriasis, and other monoclonal antibodies are in development. This review provides dermatologists and those who treat and/or manage psoriasis with a working knowledge of the scientific principles of biosimilar development and approval. It also examines real-world experience with biosimilars available for or used in dermatology that will enable physicians to make informed treatment decisions for their patients with psoriasis., Funding: Pfizer Inc.
- Published
- 2018
- Full Text
- View/download PDF
50. [Chronic, refractory ulcer on the ring finger : Manifestation of distal epithelioid sarcoma].
- Author
-
Häring NS, Strohal R, Dertinger S, and Offner F
- Subjects
- Humans, Male, Neoplasm Recurrence, Local, Sentinel Lymph Node Biopsy, Sarcoma diagnosis, Sarcoma pathology, Skin Ulcer diagnosis, Skin Ulcer pathology, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms pathology
- Abstract
The epithelioid sarcoma classic, "distal" type was first published in 1970. It is a very rare, malignant, aggressive subcutaneous soft tissue sarcoma that shows characteristic positivity for both epithelial and mesenchymal immunohistochemical markers. It grows very slowly and mostly presents in young men. Clinically the tumor is characterized as a coarse cutaneous or subcutaneous nodular induration that often ulcerates in the course of the disease. An association with trauma is often described and can lengthen time to diagnosis. Most frequently it is found on the flexural side of fingers, the back of the hands, soles of the feet, and extensor sides of arms and legs. Specific for this type of sarcoma is the progression along nerves, tendons, and fasciae. Treatment of choice should be wide excision of the tumor, sentinel node biopsy, and possibly even localized postoperative radiation therapy. Unfortunately the epithelioid sarcoma is very likely to recur and is then associated with metastases in the lung and lymph nodes.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.